SAN DIEGO--(BUSINESS WIRE)--Velia Therapeutics, a biotechnology company focused on the discovery and characterization of novel, disease relevant and druggable microproteins, today announced that Alan Saghatelian, PhD, has been named chief technology officer. A scientific co-founder of Velia Therapeutics, Dr.

圣地亚哥--（商业新闻短讯）--Velia Therapeutics是一家专注于发现和表征新型，疾病相关和可药用微蛋白的生物技术公司，今天宣布Alan Saghatelian博士被任命为首席技术官。Velia Therapeutics的科学联合创始人Dr。

Saghatelian will oversee critical development activities to optimize the company’s proprietary microprotein-based platform and advance its robust pipeline of novel therapeutics..

Saghatelian将监督关键的开发活动，以优化公司专有的基于微蛋白的平台，并推进其强大的新型治疗药物管道。。

“I am thrilled that Dr. Saghatelian, a renowned expert in human biology and co-founder of Velia, will assume the role of chief technology officer where his unmatched depth of knowledge of microproteins, experience applying new strategies to make important discoveries that accelerate the development of new medicines and extensive research background will guide the continued development of the world’s most rigorously annotated library of highly desirable microproteins,” said John McHutchison, AO, MD, president and chief executive officer at Velia Therapeutics.

Velia Therapeutics总裁兼首席执行官、医学博士John McHutchison表示：“我很高兴Saghatelian博士，一位著名的人类生物学专家和Velia联合创始人，将担任首席技术官，他对微蛋白拥有无与伦比的深度知识，有经验应用新策略做出重要发现，加速新药开发，拥有广泛的研究背景，将指导世界上注释最严格的微蛋白库的持续开发。”。

“Dr. Saghatelian will also maintain his current position at the Salk Institute in parallel with this new role, which we believe will benefit both organizations and our individual missions. He will be a valuable member of the Velia leadership team and play a critical role in accelerating our efforts to identify novel targets and harness the therapeutic potential of microproteins to treat a wide variety of diseases.”.

“Saghatelian博士在担任这一新角色的同时，还将保持他目前在索尔克研究所的职位，我们相信这将使组织和我们的个人使命受益。他将是Velia领导团队的宝贵成员，并在加速我们确定新靶点的努力和利用微蛋白治疗多种疾病的治疗潜力方面发挥关键作用。”。

Dr. Saghatelian has more than 25 years of research experience at leading academic institutions, including The Salk Institute for Biological Studies and, previously, Harvard University and The Scripps Research Institute. He is one of the pioneers of the study of microproteins and their fundamental connections to disease pathology, developing first-of-its-kind innovative platforms and identifying thousands of new human genes alongside some of the world’s top researchers.

Saghatelian博士在领先的学术机构拥有超过25年的研究经验，包括索尔克生物研究所，之前还有哈佛大学和斯克里普斯研究所。他是研究微蛋白及其与疾病病理学的基本联系的先驱之一，开发了同类创新平台，并与一些世界顶尖研究人员一起鉴定了数千个新的人类基因。

Currently, he is a professor at the Clayton Foundation Laboratories for Peptide Biology and the Dr. Frederik Paulsen Chair at The Salk Institute for Biological Sciences. In his career, Dr. Saghatelian has received numerous academic awards and honors, submitted various patent applications, and authored more than 150 publications across high impact peer-reviewed journals.

目前，他是克莱顿基金会肽生物学实验室的教授和索尔克生物科学研究所的弗雷德里克·保尔森博士主席。在他的职业生涯中，Saghatelian博士获得了许多学术奖项和荣誉，提交了各种专利申请，并在高影响力的同行评审期刊上撰写了150多篇出版物。

Dr. Saghatelian received a PhD in chemistry from The Scripps Research Institute and a BS in chemistry from the University of California, Los Angeles..

Saghatelian博士拥有斯克里普斯研究所（Scripps Research Institute）的化学博士学位和加利福尼亚大学洛杉矶分校（University of California，Los Angeles）的化学学士学位。。

“I am incredibly proud of the progress that Velia has made in applying its powerful discovery platform to develop a microprotein-based pipeline of groundbreaking therapeutics, and I look forward to working with the experienced leadership team to further advance these programs,” said Dr. Saghatelian.

Saghatelian博士说：“我为Velia在应用其强大的发现平台开发基于微蛋白的开创性治疗方法方面取得的进展感到无比骄傲，我期待着与经验丰富的领导团队合作，进一步推进这些项目。”。

“Drawing from my scientific research background and deep knowledge of Velia’s proprietary technology as a company co-founder, in this new role I am excited to support and enhance Velia’s discovery and development efforts ultimately with the aim to improve patient lives.”.

“从我作为公司联合创始人的科研背景和对Velia专有技术的深入了解来看，担任这一新角色，我很高兴能够支持和加强Velia的发现和开发工作，最终目的是改善患者的生活。”。

“When we first developed a strong interest in the microprotein field, Dr. Saghatelian was among the first calls we made to start this company,” said Leon Chen, chairman of the board at Velia Therapeutics and partner at The Column Group. “Welcoming him as chief technology officer is a full-circle moment, especially at a critical time for Velia as we continue to uncover the therapeutic potential of microproteins to fulfill significant unmet needs across therapeutic areas.

Velia Therapeutics董事会主席兼Column Group合伙人Leon Chen表示：“当我们首次对微蛋白领域产生浓厚兴趣时，Saghatelian博士是我们成立这家公司的首批人选之一。”。“欢迎他担任首席技术官是一个完整的时刻，特别是在Velia的关键时刻，因为我们继续发现微蛋白的治疗潜力，以满足治疗领域尚未满足的重大需求。

I look forward to continuing to collaborate with him in his new role at Velia.”.

我期待着在他担任Velia的新职务时继续与他合作。”。

About Velia Therapeutics

关于Velia Therapeutics

Velia Therapeutics is a biotechnology company focused on the discovery and development of a new generation of protein-based therapeutics that address the underlying causes of difficult-to-treat diseases. The company is the scientific leader in identifying disease-relevant microproteins hidden in the dark matter of the human proteome.

Velia Therapeutics是一家生物技术公司，专注于发现和开发新一代基于蛋白质的疗法，以解决难以治疗的疾病的根本原因。该公司是识别隐藏在人类蛋白质组暗物质中的疾病相关微蛋白的科学领导者。

Harnessing its proprietary platform technology and unique expertise in microprotein discovery, Velia is focused on uncovering new drug targets and developing first-in-class therapies for renal, inflammatory and immunologic disorders and other diseases. The company’s innovative technology for identifying novel protein coding sequences in the proteome is based upon the seminal work of its world-renowned scientific founders, Eric Olson, PhD, Alan Saghatelian, PhD, Richard Scheller, PhD, and Jonathan Weissman, PhD; all recognized leaders in protein biology.

利用其专有的平台技术和在微蛋白发现方面的独特专业知识，Velia专注于发现新的药物靶标，并开发针对肾脏，炎症和免疫疾病以及其他疾病的一流疗法。该公司用于识别蛋白质组中新的蛋白质编码序列的创新技术基于其世界著名科学创始人埃里克·奥尔森（Eric Olson）博士，艾伦·萨哈特利安（Alan Saghatelian）博士，理查德·谢勒（Richard Scheller）博士和乔纳森·魏斯曼（Jonathan Weissman）博士的开创性工作；所有公认的蛋白质生物学领导者。

Led by an experienced management team and funded by top-tier venture groups, the company is poised to break new ground in protein-based therapeutics to transform medical care and improve patients’ lives. More information about Velia Therapeutics is available at www.veliatx.com and on LinkedIn..

该公司由经验丰富的管理团队领导，由顶级风险投资集团资助，准备在基于蛋白质的疗法方面开辟新天地，以改变医疗保健并改善患者的生活。有关Velia Therapeutics的更多信息，请访问www.veliatx.com和LinkedIn。。